Author + information
- Received July 9, 2002
- Revision received September 16, 2002
- Accepted October 4, 2002
- Published online February 19, 2003.
- ↵*Reprint requests and correspondence:
Dr. E. Magnus Ohman, Professor of Medicine, Chief, Division of Cardiology, University of North Carolina at Chapel Hill, 338 Burnett-Womack Building, CB #7075, Chapel Hill, North Carolina 27599 USA.
Over the past decade, there has been a progressive evolution of cardiac marker testing in patients with acute coronary syndromes (ACS). This has not only resulted in a dramatic shift in how we view the diagnosis of myocardial infarction (MI), but it has also extended the role of cardiac marker testing into risk stratification and guidance of treatment decisions. By the year 2000, the development of highly sensitive and cardiac-specific troponin assays had resulted in a consensus change in the definition of MI, placing increased emphasis on cardiac-marker testing with troponins as the new gold standard. Furthermore, and perhaps more importantly, the role of the troponins as superior markers of subsequent cardiac risk in ACS patients became firmly established. Most recently, the supportive role of these markers in identifying patients with ACS who may derive particular benefit from potent anti-thrombotic and anti-platelet therapy or early invasive treatment strategies has been demonstrated. This paper will review the evolution of these important roles of troponin testing for risk stratification in ACS.
☆ Please refer to the Trial Appendix at the back of this supplement for the complete list of clinical trials.
Dr. Newby has received grant support from Roche Diagnostics, DadeBehring, Inc., and Roche Pharmas. Dr. Newby has been on the speakers’ bureau for Biosite, Inc. Dr. Ohman has received research grants from the following organizations: Roche, Dade, Centecor, Merck, and Millennium.
- Received July 9, 2002.
- Revision received September 16, 2002.
- Accepted October 4, 2002.
- American College of Cardiology Foundation